BIVIMEDIUM SIGNALFINANCIAL10-K

BIVI significantly reduced operating losses and liabilities while adding Long COVID as a new therapeutic target, though cash position declined substantially.

The company has dramatically improved its financial position with a 45% reduction in net losses and 74% decrease in total liabilities, suggesting better cost management and debt reduction. However, the 26% decline in cash reserves to $17.5M raises questions about runway duration despite the improved burn rate.

Comparing 2025-08-15 vs 2024-09-30View on EDGAR →
FINANCIAL ANALYSIS

BIVI showed significant operational improvement with R&D expenses falling 60% and net losses declining 45%, while simultaneously reducing total liabilities by 74% and improving stockholders' equity by 23%. Despite these positive trends, cash declined substantially by $6.3M to $17.5M, though the improved operating cash flow burn rate suggests better capital efficiency. The overall picture indicates a company that has successfully reduced costs and debt burden but needs to monitor cash runway carefully.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
-75.7%
$9.4M→$2.3M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-73.7%
$9.7M→$2.6M

Liabilities reduced 73.7% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-59.9%
$23.1M→$9.3M

R&D spending cut 59.9% — could signal cost discipline or concerning reduction in innovation investment.

Net Income
P&L
+45.4%
-$32.1M→-$17.5M

Net income grew 45.4% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+43.9%
-$32.2M→-$18.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Interest Expense
P&L
-32.7%
$4.3M→$2.9M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Operating Cash Flow
Cash Flow
+31.9%
-$27.9M→-$19.0M

Operating cash flow surged 31.9% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
-26.4%
$23.8M→$17.5M

Cash decreased 26.4% — monitor burn rate and upcoming capital needs.

Stockholders Equity
Balance Sheet
+22.6%
$15.5M→$19.0M

Equity base grew 22.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
-14.5%
$25.2M→$21.6M

Total assets contracted 14.5% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2025-08-15
PRIOR — 2024-09-30
ADDED
There were 7,534,225 shares of the Registrant s Class A Common Stock, $0.0001 par value per share, outstanding as of August 15, 2025.
( NeurMedix ) a privately held clinical-stage pharmaceutical company and a related party in June 2021.
Bezisterim, the approved generic name for NE3107 is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action.
Food and Drug Administration ( FDA ), represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from AD , 1 million Americans suffering from PD and Long COVID affects approximately 20 million adults in the US, and millions more worldwide.
In neurodegenerative disease, the Company s drug candidate bezisterim is an orally bioavailable, Blood Brain Barrier ( BBB )-permeable, and anti-inflammatory agent that is an insulin-sensitizer.
In addition, it is not immunosuppressive and has a low risk of drug-drug interaction.
Bezisterim inhibits activation of inflammatory extracellular single regulated kinase ( ERK ) and nuclear factor kappa-light-chain-enhancer of activated B cells ( NF B ) (including interactions with tumor necrosis factor ( TNF ) signaling and other relevant inflammatory pathways) that lead to neuroinflammation and insulin resistance.
By binding to ERK and selectively modulating NF B activation and TNF- production bezisterim does not interfere with their homeostatic functions, BioVie believes that bezisterim may offer clinical improvements in several disease indications, including PD, AD and long COVID.
BioVie has conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate AD (NCT04669028).
Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer s Disease (CTAD) annual conference in December 2022.
REMOVED
All statements other than statements of historical fact are statements that could be deemed forward-looking statements.
The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
( NeurMedix ) a privately held clinical-stage pharmaceutical company and a related party in June 2021 .
In April 2024, the Company announced that the United States Adopted Names Council, and the World Health Organization International Nonproprietary Names expert committee had approved bezisterim as the non-proprietary (generic) name for NE3107.
Bezisterim (NE3107) is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action.
Food and Drug Administration ( FDA ), represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from AD and 1 million Americans suffering from PD.
In neurodegenerative disease, bezisterim (NE3107) inhibits activation of inflammatory extracellular signal-regulated kinase ( ERK ) and nuclear factor kappa-light-chain-enhancer of activated B cells ( NF B ) (including interactions with tumor necrosis factor ( TNF ) signaling and other relevant inflammatory pathways) that lead to neuroinflammation and insulin resistance.
Bezisterim (NE3107) does not interfere with their homeostatic functions (e.g., insulin signaling and neuron growth and survival).
Both inflammation and insulin resistance are drivers of AD and PD.
About Inflammation and Bezisterim s (NE3107 s) Mechanism of Action Neuroinflammation, insulin resistance, and oxidative stress are common features in the major neurodegenerative diseases, including AD, PD frontotemporal lobar dementia, and Amyotrophic lateral sclerosis ( ALS ).
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →